CorAccess – Tissue Strengthening Access Port for Cardiac Surgery

Robert Guyton, M.D.
Murali Padala, Ph.D.

Cale Lennon
Assistant Director
OTT Breakfast Club
December 13th, 2011
Transapical Cardiovascular Devices

- Simple, direct and less invasive access to left ventricle and valves

# of candidates in U.S. (2012)*

- Ventricular Assist: 4,500
- Transapical Aortic Valve Replacement: 91,000
- Transapical Mitral Valve Repair: 160,000

*Source: Frost & Sullivan
Opportunity: Reducing Transapical Complications

- Ventricular apex thins and weakens in elderly patients/those with chronic heart disease
- Dumont et al.: 29% of TAVR patients had ventricular tearing*
- Risk of rupture during apex closure

CorAccess Device

- Principle: Tissue strengthening via controlled, localized thermal strengthening
CorAccess – Animal Studies

Insertion into LV apex

Localized tissue heating/strengthening

Closure w/biocompatible plug
Safety of Thermal Stabilization

- Apical access already accepted as safe
- Precise, limited treatment area with HIFU
- Ventricle mechanical function preserved
- EKG not affected
- Less tissue trauma compared to suturing
CorAccess Competition

Apical Port Access Systems
- Onset Medical
- Cardious Inc
- Apica
- Cardiovascular
- CardioVantage
- Medical
- Edwards
- Lifesciences
- Medtronic

Apical Strengthening Systems
None

Highly Leverageable Technology/IP Platform
(Provisional patent pending through Emory OTT)
CorAccess – Value Proposition

- **Reduces procedural risk** by increasing the regional myocardial strength
- **Improves procedural ease** by one-shot closure of the access site
- **Enhances patient outcomes** by avoiding major surgery